The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. - Wikidata - awgldk - TriplyDB

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

http://www.wikidata.org/entity/Q40399567

about

Modulation of Autophagy by Sorafenib: Effects on Treatment Response Targeting Mcl-1 for the therapy of cancer Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation The study of a novel sorafenib derivative HLC-080 as an antitumor agent Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1 Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer Phase II study of sorafenib in patients with relapsed or refractory lymphoma.A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.Targeted therapy in melanoma.Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed.A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor.Phase I study of sorafenib in patients with refractory or relapsed acute leukemias A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.Multiple mechanisms mediate resistance to sorafenib in urothelial cancer Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo Cholangiocarcinoma: molecular pathways and therapeutic opportunities The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.

P2860

Q26745320-A1D36835-9FAF-4426-A384-43F2A9630E89 Q27011870-05669E29-4E04-4BBE-A6B5-B675EF0B4370 Q27490901-A44D0379-A72C-4512-9178-17139E92FAF8 Q27649579-579C2226-DA63-4011-9ADC-A040BE04BE5E Q28540521-02188DFF-8C93-42B7-9DB1-1FCBCBD24AD0 Q28830045-B5759C5C-A5D8-4A12-BEA0-0B79D92AC2E7 Q30317831-F62DB0D3-F7AC-4206-BEA9-3AFCD78BD603 Q33266778-46E9147D-07C7-4FC0-AC9E-3B901BC74401 Q33326515-24B2957C-606A-4FA0-B89C-C421310C85F6 Q33401136-4063E9DD-19E7-4F23-A7FC-490836331D52 Q33404952-7E5300AC-713B-46DA-9CFB-DE477967B6A1 Q33509293-317E8340-6E22-4F4B-AABF-CB62A82C966F Q33514138-E8347C0A-FC04-4862-9C99-7F23C919807B Q33569854-A98FD055-8FDA-4F28-A1F3-68BE804C4FB2 Q33573107-15DD3C5A-C0AB-45E6-86E2-E4751A9A012F Q33728138-A496C24F-8C2E-4E2F-9A9B-3E0E4B87A247 Q33772438-89C3B1C7-BD26-4259-B474-C81F4DD064D9 Q33780701-84E277D1-4628-47F3-B9B3-A04136920D94 Q33780816-55008507-97AA-4F8C-B49A-516BB69A82FA Q33900952-742CF65C-DEED-42CC-B39C-964E0377EB63 Q33917547-3EFCE35C-7319-47F7-BF75-69844B91B5D6 Q33936548-F99898C0-C02B-412F-AA3B-7332E16AB6CD Q34063343-A8DEDEB4-BEC2-453A-8CB0-E3E5976CC07D Q34241371-3CE5620E-8192-4195-B65F-CA6F9F4BC845 Q34329204-A707EED2-0B99-4326-BAF7-BCFF39A0B39B Q34408875-D6DA1C17-3BB0-45F8-9806-79642E00332D Q34451540-1D57D2A5-503C-4E73-9568-C267C53DC0C3 Q34615116-4F6B4CB6-8971-4AA1-B91E-3383211161E1 Q34685436-C39EBA62-71AC-4B47-BBD6-DC9A478152ED Q34689078-31AC9DEF-913D-4B4F-A516-BADFB68190A4 Q34788849-6F05E5D6-BFBA-41CF-AEF3-0605AA2B9DD8 Q34837850-D268527E-D6B7-49C7-844D-B85944E4D758 Q34959174-BF0B5E6C-7559-4CFB-A731-9715A19FF6DA Q35038725-154D0C97-4772-4D5B-B43A-F3B5490CD7EB Q35080145-D0FE1D23-6896-4A7B-A428-1A84376A5694 Q35125118-89490BF9-0AD4-4D57-8952-9B8DADA50BA8 Q35147986-A7EC17E7-101D-4E55-ADF5-01F3221A8572 Q35190181-BE5A017C-1265-459A-A5B5-7F0B83DBC7AD Q35570953-B818C93A-56A5-40EC-AB54-ABB80C75426B Q35740894-64843350-C546-49AA-8B3F-BEBCC8EE8800

P2860

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

http://www.wikidata.org/entity/Q40399567

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.

@en

type

label

The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.

@en

prefLabel

The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.

@en

P1433

Q40399567-7225DE93-141E-43A7-87E4-3BF222592B21

P1476

Q40399567-4DB1BBA2-B18A-4861-AA3A-5D66CB36A5FE

P2093

Q40399567-41E39C6F-5E5C-40D9-B41E-560E4EA49B4D

Q40399567-4B613DFC-84B8-42A6-B464-85E801CEB3C2

Q40399567-9114136E-7947-492E-8E2E-4E684F3009E4

Q40399567-BB930B7B-80EF-4748-B611-A7DAFE0F6F9E

Q40399567-CB8A2AC1-38EB-4BAE-9F3A-1691B0C68E46

Q40399567-D6A5B3B9-9C07-43E6-BC2B-14E316787906

P2860

Q40399567-001B1C81-B14D-455F-8A2A-27DA40C2FEB9

Q40399567-802F6533-9929-4DD8-91FF-748927CB460A

Q40399567-B037F529-82B4-4596-B3D8-2E1DB94233BE

Q40399567-CBA018EB-9C6B-431D-ABF6-B5B7E6EA74DC

Q40399567-D5E54E05-623F-4FD8-9E2E-A1843EBDFD2C

Q40399567-E5969613-F2E1-4651-8A24-D9DDE5BD778F

P2888

Q40399567-CAF06D31-FA76-441C-A024-D2DE5E164259

P304

Q40399567-30E036A6-B0F4-4686-A117-463FEFE425FC

P31

Q40399567-745A25F0-F19D-4A1F-BB53-E6732457E25D

P356

Q40399567-C4F2E9EE-8114-4446-A84E-83C2A45C169F

P407

Q40399567-84412B72-945F-40E2-8B85-52D71B681091

P433

Q40399567-09227FE8-384B-4B8C-990C-226DA9D050F6

P478

Q40399567-437BD2D3-B036-457C-A796-C0C3AA86C73D

P50

Q40399567-8E67E793-BA0F-4DEE-9A57-0E04FAB49AE4

P577

Q40399567-5128DFD4-99F0-4E43-B424-289298C806C4

P5875

Q40399567-F720080B-38A5-46ED-BFD0-D97C580BED04

P6179

Q40399567-E20E8D1F-424E-4AE6-B2FE-C6629D6B4652

P698

Q40399567-3CE334E5-C395-4C62-A1A9-434982F0784C

P356

P1433

P1476

The role of Mcl-1 downregulati ...... ikinase inhibitor BAY 43-9006.

@en

P2093

Alex A Adjei

http://www.w3.org/2001/XMLSchema#string

Christopher A Carter

http://www.w3.org/2001/XMLSchema#string

Chunrong Yu

http://www.w3.org/2001/XMLSchema#string

Laura M Bruzek

http://www.w3.org/2001/XMLSchema#string

Scott H Kaufmann

http://www.w3.org/2001/XMLSchema#string

Xue Wei Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.

Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress.

Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition.

Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

P2888

P304

6861-6869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1208841

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Gregory J Gores

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7737697

http://www.w3.org/2001/XMLSchema#string

P6179

1053064977

http://www.w3.org/2001/XMLSchema#string

P698

16007148

http://www.w3.org/2001/XMLSchema#string